NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, announced the appointment of Mr. Jon Coulter as Non-Executive Chairman. Mr. Coulter has been a Board Member of NorthStar since 2010 and was appointed to the post effective March 26, 2025. He succeeds Mr. Stephen Merrick, who joined NorthStar in 2016, has served as Executive Chairman since July 2023 and is now retiring from that position.
The changes announced are the next step in a thoughtfully planned leadership succession that reflects and supports NorthStar’s long-term strategy for continued growth and corporate development to become a global leader in the radiopharmaceutical industry.
Also Read: Fresenius Medical Care Launches First €600 Million Tranche of €1 Billion Share Buyback Program
“I am honored to assume the role of Non-Executive Chairman at NorthStar and look forward to supporting NorthStar’s leadership team in driving continued growth,” said Mr. Coulter “NorthStar’s industry-leading reputation is grounded in technological innovation, successful execution and proven expertise. The company’s portfolio includes promising therapeutic radioisotopes and both modern infrastructure and capabilities to help advance development on of therapeutic radiopharmaceuticals to treat a broad range of diseases. We have a state-of-the-art patient dose development and manufacturing facility and are the only U.S. based company to have co-located commercial scale multi-radioisotope production and radiopharmaceutical manufacturing. We believe our portfolio of products and services can help unlock the promise of radiopharmaceuticals to meet the needs of patients who today have far too few effective treatment options.”
Click here to join our WhatsApp channel here
“It has been exceptionally rewarding to have served as a senior leader at the company for nine years, and I am proud to have led the organization during a transformative period of growth and development. During that time we evolved from a pre-commercial, single project company to a commercial stage business with a diversified portfolio of opportunities that can help transform patient care”, said Stephen Merrick. “I am confident that our new leadership can continue to drive this growth and wish Jon and the leadership team continued success.”
Commenting on the leadership transition and Coulter’s appointment, Frank Scholz, President and CEO of NorthStar said, “On behalf of NorthStar’s employees and its’ executive team, I would like to congratulate Jon on this appointment, and look forward to working with him to pursue the rich opportunities before us. It has been a privilege to work alongside Steve and I would like to thank him for his many contributions and years of dedication to the business. As he steps down, I am grateful for the strong foundation he has built and am excited to continue to build upon it for future growth.”
